VivoSeq
Oncology

Carcinosarcoma

18

Pipeline Programs↗

2

Active Trials↗

13

Companies Involved↗

Carcinosarcoma is an emerging landscape with 18 programs across 13 companies. The most active players are Teva, Amgen, Eli Lilly. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

0/100

Mech. Concentration

18/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

4 programs

Phase 2L

Leap Therapeutics, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

65%

Small molecule

13 of 20 classified programs — the dominant modality here.

35%ALL OTHERSMonoclonal antibody630%Protein / enzyme15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Withdrawn2 · 17%
Recruiting2 · 17%
Unknown status2 · 17%

Clinical Trials

Trial Activity

12 trials

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Recruiting·AARCAGY/ GINECO GROUP·Phase 2/3·NCT03651206·138 enrolled
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05559879·37 enrolled
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Completed·UUniversity of Oklahoma·Phase 1·NCT03206177·26 enrolled
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Completed·National Cancer Institute (NCI)·Phase 2·NCT00025506·55 enrolled
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Completed·LLeap Therapeutics, Inc.·Phase 2·NCT03395080·111 enrolled
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Completed·IImperial College London·Phase 2·NCT03648489·134 enrolled
Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)
Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT02993705·45 enrolled
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
Completed·GGynecologic Oncology Group·Phase 1·NCT00352300·43 enrolled
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT04149275
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Withdrawn·AAustralia New Zealand Gynaecological Oncology Group·Phase 2·NCT03933761
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Unknown status·YYonsei University·Phase 2·NCT05224999·28 enrolled
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Unknown status·FFudan University·Phase 2·NCT05265793·45 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)